News

Algorithm Can Guide Prescribing for Diabetes


 

A new one-page treatment algorithm for type 2 diabetes from the American Association of Clinical Endocrinologists is aimed at assisting physicians in choosing appropriate therapy from among all the approved classes of glucose-lowering medications.

The algorithm stratifies treatment based on hemoglobin A1c values, with separate treatment pathways for patients with levels of 6.5%-7.5%, 7.6%-9.0%, and greater than 9.0% (Endocrine Practice 2009;15:541-59).

In general, patients with HbA1c values of 7.5% or lower can start with monotherapy, with metformin considered the “cornerstone” but with three other drug classes included as alternatives. Patients with values of 7.6%-9.0% typically require dual therapy. The algorithm advises insulin for patients with values higher than 9% who already are receiving other treatments or who are drug-naive and symptomatic. For patients with levels higher than 9% who are drug-naive but asymptomatic, dual or triple combination therapies can be used.

“This is an authoritative, up-to-date, practical, and simple algorithm which should provide meaningful guidance to physicians as they make their therapeutic decisions,” said Dr. Helena W. Rodbard, cochair of the consensus panel that developed the algorithm, which is officially a publication of both AACE and its educational branch, the American College of Endocrinology (ACE).

“It's an easily readable clinical point-of-care tool designed to assist endocrinologists, primary care physicians, and others involved in the care of patients with type 2 diabetes,” said Dr. Paul S. Jellinger, panel cochair who, like Dr. Rodbard, is a former president of both AACE and ACE.

Both Dr. Jellinger and Dr. Rodbard emphasized that the algorithm—written by a panel of 14 practicing endocrinologists—accurately represents the way a majority of experienced endocrinologists approach the treatment of type 2 diabetes.

In contrast to a recently revised algorithm from the American Diabetes Association and the European Association for the Study of Diabetes (Diabetes Care 2009;32:193-203), the AACE/ACE algorithm fully incorporates all classes of drugs approved to treat type 2 diabetes and places less emphasis on the drug costs.

“Most previous algorithms placed an undue emphasis on the cost of medications. Drugs can be expensive, but the cost of medications is only about 11% of the total cost of care of the population with diabetes. We need to consider the total cost of care, which is overwhelmingly driven by the cost of complications,” said Dr. Rodbard, an endocrinologist in Rockville, Md.

Dr. Jellinger, who practices endocrinology in Hollywood, Fla., added: “We placed a big emphasis on safety, particularly in terms of hypoglycemia. We included GLP-1 mimetics, DPP4 inhibitors and TZDs, along with metformin, since those classes have no potential for hypoglycemia. At the same time, we have downgraded the use of sulfonylureas due to their increased risk for hypoglycemia. By avoiding hypoglycemia, you avoid hospitalizations, which are far more expensive than the medicine.”

But Dr. David M. Nathan, chair of the ADA/EASD consensus panel, said he doesn't believe it makes sense to include the additional agents as alternatives to metformin for first-line therapy or to list so many drug classes at every level. “The ADA/EASD guidelines were specifically formulated to help busy nonspecialists make informed choices from the large number of treatments that have become available in the last decade. With that in mind, the ADA/EASD consensus committee tried to narrow the choices based on effectiveness, safety, tolerability, acceptability, and cost.”

In contrast, “AACE has taken a different tack and included all approved medications. Their more complex algorithm offers more choices but, in our opinion, doesn't help the busy clinician make the best choices,” said Dr. Nathan, professor of medicine at Harvard University and director of the diabetes center at Massachusetts General Hospital, Boston.

“The TZD, DPP-4, and AGI they recommend are manyfold more expensive than metformin, have far less clinical experience than with metformin, are no safer—and probably less safe for TZD—and have the same frequency or far more side effects,” he added.

Accompanying the AACE algorithm is a text document that explains the rationale for each treatment option and other issues, which include the following:

▸ Lifestyle (diet and exercise) modifications are essential for all patients with diabetes, but delaying pharmacotherapy to allow for lifestyle modifications to take effect is likely to be inadequate. Counseling regarding lifestyle changes should be initiated along with diabetes self-management education and medications.

▸ Achieving an HbA1c of 6.5% is the primary goal, but this goal must be individualized based on factors such as comorbid conditions, hypoglycemia history, and life expectancy.

▸ Effectiveness of therapy must be evaluated frequently, typically every 2-3 months.

▸ Safety and efficacy should be given greater priority than cost of medications because the cost of drugs is only a small part of the total cost of diabetes care.

Pages

Recommended Reading

Top Five Challenges In Osteoporosis Tx
MDedge Internal Medicine
Denosumab Increased BMD in 6-Year Study
MDedge Internal Medicine
Draft Guidelines for Grave's Tx Stress Options
MDedge Internal Medicine
Guidelines Update Approach To Small Thyroid Ca Tumors
MDedge Internal Medicine
Therapy, Vitamin D Reduce Falls, Readmissions
MDedge Internal Medicine
Alter Bone Care in Patients on Glucocorticoids
MDedge Internal Medicine
FRAX 10-Year Hip Fracture Predictions Match Incidence
MDedge Internal Medicine
Diabetes, Cancer Link Is New Research Focus
MDedge Internal Medicine
Metformin Investigated as Possible Anticancer Treatment
MDedge Internal Medicine
Bariatric Surgery Lowers Risk of Cancer Death
MDedge Internal Medicine